Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > Close to Update

<< Previous

Bullboard Posts

Next >>

Comment by MrMonkon Jun 04, 2013 10:05pm

105 Views

Post# 21485318

RE: Close to Update

Not a whole lot of volume, but a nice move up in a short period of time. Interesting to see what happens over the next couple of trading sessions - whether the rise will continue. Resource update seems past-due - ARZ/Hecla needs to approve the release and I'm sure this is the hold-up. Part of me (a growing part) thinks that we would be far better off on our own - take the $11 million gift and move on without ARZ/Hecla...

-- MM

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects